07 August 2025 : Database Analysis
Trends and Efficacy in Clostridioides difficile Infection Management at a Polish Clinical Hospital
Jarosław Drobnik
ABDEG 1, Piotr Pobrotyn ADEFG 2*, Urszula Grata-Borkowska DF 1, Katarzyna Madziarska DE 3, Mateusz Baran ABCDEF 4
DOI: 10.12659/MSM.948254
Med Sci Monit 2025; 31:e948254
Table 4 CDI mortality by treatment used at the UCHW in 2016–2018.
| Method of treatment | The number of patients receiving the given treatment | Percentage of patients receiving a given treatment | The number of patients who have died receiving a given treatment | Mortality |
|---|---|---|---|---|
| No chemotherapeutic | 10 | 3.16% | 2 | 20.00% |
| Metronidazole only | 85 | 26.90% | 12 | 14.12% |
| Vancomycin only | 65 | 20.57% | 13 | 20.00% |
| Metronidazole and vancomycin | 128 | 40.51% | 45 | 35.16% |
| Rifaximin plus metronidazole and/or vancomycin | 23 | 7.28% | 6 | 26.09% |
| Fidaxomicin plus vancomycin or fidaxomicin plus vancomycin and metronidazole | 5 | 1.58% | 0 | 0.00% |
| All patients | 316 | 100.00% | 78 | 24.68% |